Show simple item record

dc.contributor.authorMaramai, Samuele
dc.contributor.authorBenchekroun, Mohamed
dc.contributor.authorGabr, Moustafa T
dc.contributor.authorYahiaoui, Samir
dc.date.accessioned2020-10-21T12:47:25Z
dc.date.available2020-10-21T12:47:25Z
dc.date.issued2020-06-30
dc.identifier.citationBiomed Res Int. 2020 Jun 30;2020:5120230. doi: 10.1155/2020/5120230.en_US
dc.identifier.pmid32714977
dc.identifier.doi10.1155/2020/5120230
dc.identifier.urihttp://hdl.handle.net/10033/622524
dc.description.abstractNeurodegenerative diseases represent nowadays one of the major health problems. Despite the efforts made to unveil the mechanism leading to neurodegeneration, it is still not entirely clear what triggers this phenomenon and what allows its progression. Nevertheless, it is accepted that neurodegeneration is a consequence of several detrimental processes, such as protein aggregation, oxidative stress, and neuroinflammation, finally resulting in the loss of neuronal functions. Starting from these evidences, there has been a wide search for novel agents able to address more than a single event at the same time, the so-called multitarget-directed ligands (MTDLs). These compounds originated from the combination of different pharmacophoric elements which endowed them with the ability to interfere with different enzymatic and/or receptor systems, or to exert neuroprotective effects by modulating proteins and metal homeostasis. MTDLs have been the focus of the latest strategies to discover a new treatment for Alzheimer's disease (AD), which is considered the most common form of dementia characterized by neurodegeneration and cognitive dysfunctions. This review is aimed at collecting the latest and most interesting target combinations for the treatment of AD, with a detailed discussion on new agents with favorable in vitro properties and on optimized structures that have already been assessed in vivo in animal models of dementia.en_US
dc.language.isoenen_US
dc.publisherHindawien_US
dc.rightsAttribution-NonCommercial-ShareAlike 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/4.0/*
dc.titleMultitarget Therapeutic Strategies for Alzheimer's Disease: Review on Emerging Target Combinations.en_US
dc.typeReviewen_US
dc.identifier.eissn2314-6141
dc.contributor.departmentHIPS, Helmholtz-Institut für Pharmazeutische Forschung Saarland, Universitätscampus E8.1 66123 Saarbrücken, Germany.en_US
dc.identifier.journalBioMed research internationalen_US
dc.source.volume2020
dc.source.beginpage5120230
dc.source.endpage
refterms.dateFOA2020-10-21T12:47:26Z
dc.source.journaltitleBioMed research international
dc.source.countryUnited States


Files in this item

Thumbnail
Name:
Maramai et al.pdf
Size:
1.509Mb
Format:
PDF
Description:
Open Access publication

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-ShareAlike 4.0 International
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-ShareAlike 4.0 International